Abstract:Exosomes have been implicated in inflammation-related diseases, such as hepatic fibrosis (HF) and renal fibrosis, via transferring bioactive cargoes to recipient cells. This study aimed to investigate the possible effect of hepatic stellate cell (HSC)-derived exosomes on the initiation and development of HF by delivering microRNA (miR)-199a-5p. In HF rats with cholestasis induced by ligating the common bile duct, miR-199a-5p was upregulated while SIRT1 was downregulated in liver tissues from bile duct ligation (BDL) rats compared with that of sham rats. Furthermore, miR-199a-5p expression was upregulated, but the mRNA and protein expression levels of SIRT1 were downregulated in TGF-β1-activated LX-2. miR-199a-5p promoted the proliferation and further activation of LX-2 and enhanced the expression levels of the HF markers COL1A1 and α-SMA. Subsequently, the binding of miR-199a-5p to the 3′UTR of SIRT1 mRNA was predicted by bioinformatics websites and evidenced by fluorescent reporter assay. Knocking down SIRT1 enhanced the abilities of LX-2 cell proliferation, migration, and colony formation and increased the expression levels of the HF markers α-SMA and COL1A1. LX-2-derived exosomal miR-199a-5p transferred to LX-2 and THLE-2, inhibited the proliferation of THLE-2, and promoted the epithelial mesenchymal transition (EMT) and senescence of THLE-2. Furthermore, in vivo results suggested that miR-199a-5p overexpression aggravated HF in BDL rats; increased miR-199a-5p, α-SMA, and COL1A1 expression levels; and significantly upregulated the serum ALT, AST, TBA, and TBIL levels. However, reverse results were obtained with inhibited miR-199a-5p expression. In conclusion, HSC-derived exosomal miR-199a-5p may promote HF by accelerating HSC activation and hepatocyte EMT by targeting SIRT1, suggesting that miR-199a-5p and SIRT1 may serve as potential therapeutic targets for HF.

Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation

Liver Fibrosis Causes Downregulation of Mirna-150 and Mirna-194 in Hepatic Stellate Cells, and Their Overexpression Causes Decreased Stellate Cell Activation

MicroRNA-101 Suppresses Liver Fibrosis by Downregulating PI3K/Akt/mTOR Signaling Pathway

MicroRNA-146b Regulates Hepatic Stellate Cell Activation Via Targeting of KLF4.

MicroRNA-195-3p promotes hepatic stellate cell activation and liver fibrosis by suppressing PTEN expression

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

MicroRNA-130a and -130B Enhance Activation of Hepatic Stellate Cells by Suppressing PPARγ Expression: A Rat Fibrosis Model Study.

Anti-Liver Fibrosis Role of miRNA-96-5p via Targeting FN1 and Inhibiting ECM-Receptor Interaction Pathway

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

MicroRNA-942 mediates hepatic stellate cell activation by regulating BAMBI expression in human liver fibrosis

miRNA‐130b‐5p promotes hepatic stellate cell activation and the development of liver fibrosis by suppressing SIRT4 expression

MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7.

HSC-derived exosomal miR-199a-5p promotes HSC activation and hepatocyte EMT via targeting SIRT1 in hepatic fibrosis

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways.

Mir-185 Inhibits Fibrogenic Activation of Hepatic Stellate Cells and Prevents Liver Fibrosis.

MicroRNA-194 Inactivates Hepatic Stellate Cells and Alleviates Liver Fibrosis by Inhibiting AKT2.

Integration of high‑throughput data of microRNA and mRNA expression profiles reveals novel insights into the mechanism of liver fibrosis.

Regulatory Effects of Micrornas on Hepatic Stellate Cell Activation and Liver Fibrogenesis

MiR-22-3p and Mir-29A-3p Synergistically Inhibit Hepatic Stellate Cell Activation by Targeting AKT3

MicroRNA-134 Deactivates Hepatic Stellate Cells by Targeting TGF-β Activated Kinase 1-Binding Protein 1.